Doxazosin in the treatment of benign prostatic hyperplasia. A review of the safety profile in older patients

Kirby, RS; Jardin, A

doi:10.1038/sj.pcan.4500211

Cited by 7 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, dox administration to normotensive patients does not significantly decrease blood pressure (34). The established safety and efficacy of dox, along with its potent antiproliferative and proapoptotic effects, make it an attractive potential therapy for pituitary adenomas, particularly because we observed inhibition of pituitary tumor cell proliferation with similar or lower dox concentrations than those previously shown to inhibit prostate cancer growth.…”

Section: Fig 7 Dox Treatment Inhibits Pituitary Corticotroph Tumor mentioning

confidence: 57%

α1-Adrenergic Receptor Antagonists: Novel Therapy for Pituitary Adenomas

Fernando

Heaney

2005

Molecular Endocrinology

View full text Add to dashboard Cite

Pituitary tumors are common and cause considerable morbidity due to local invasion and altered hormone secretion. Doxazosin (dox), a selective alpha(1)-adrenergic receptor antagonist, used to treat hypertension, also inhibits prostate cancer cell proliferation. We examined the effects of dox on murine and human pituitary tumor cell proliferation in vitro and in vivo. dox treatment inhibited proliferation of murine pituitary tumor cells, induced G(0)-G(1) cell cycle arrest, and reduced phosphorylated retinoblastoma levels. In addition, increased annexin-fluorescein isothiocyanate immunoreactivity and cleaved caspase-3 levels, in keeping with dox-mediated apoptosis, were observed in the human and murine pituitary tumor cells, and dox administration to mice, harboring corticotroph tumors, decreased tumor growth and reduced plasma ACTH levels. dox-mediated antiproliferative and proapoptotic actions were not confined to alpha-adrenergic receptor-expressing pituitary tumor cells and were unaffected by cotreatment with the alpha-adrenergic receptor blocker, phenoxybenzamine. dox treatment led to reduced phosphorylated inhibitory kappaB (IkappaB)-alpha expression, and nuclear factor-kappaB transcription and decreased basal and TNFalpha-induced proopiomelanocortin transcriptional activation. These results demonstrate that the selective alpha(1)-adrenergic receptor antagonist dox inhibits pituitary tumor cell growth in vitro and in vivo by mechanisms that are in part independent of its alpha-adrenergic receptor-blocking actions and involve down-regulation of nuclear factor-kappaB signaling. dox is proposed as a possible novel medical therapy for pituitary tumors.

show abstract

Section: Fig 7 Dox Treatment Inhibits Pituitary Corticotroph Tumor mentioning

confidence: 57%

α1-Adrenergic Receptor Antagonists: Novel Therapy for Pituitary Adenomas

Fernando

Heaney

2005

Molecular Endocrinology

View full text Add to dashboard Cite

show abstract

“…He has been bothered with episodic vertigo every early morning for five years. Doxazosin or terazosin, longacting selective α1-antagonist, is known to treat benign prostatic hyperplasia and hypertension by relaxing smooth muscle of vessels, urinary bladder and prostate; however, it could induce dizziness (vertigo), fatigue, hypotension, edema and dyspnea via the same mechanism [3,4]. α1-antagonists have been discontinued after 1 st -time emergency, but symptom did not relieve any more; thus, symptom was by far not a side effect of α1-antagonist.…”

Section: Discussionmentioning

confidence: 99%

Frequent Episodic Vertigo is an Unexpected Side Effect of Flutamide

Chen¹,

Chen²

2011

View full text Add to dashboard Cite

An 82-year-old male suffered from prostatic cancer five years ago. Since then, he has taken flutamide and was bothered with episodic vertigo (EV) every morning. In order to treat prostatic cancer, flutamide was not discontinued, but conservative treatment and life-style change were recommended. Finally, EV actually subsided. Herein, we report the rare case, in which EV was an unexpected side effect of flutamide. Herein we review his whole history, physical examination, vestibular function test, electronystagmogram, caloric test, awake encephalogram, blood examinations, color-coded duplex ultrasonogram and magnetic resonance imaging/angiogram to suggest a mechanism of flutamide responsible for EV

show abstract

“…Effects can be seen in some men within 48 hours of starting treatment. The most commonly reported side‐effects are headaches, dizziness, postural hypotension, retrograde ejaculation and drowsiness 9–12 . First doses of alfuzocin, prazocin and terazosin may cause collapse (e.g.…”

Section: Managing Bph‐associated Lutsmentioning

confidence: 99%

Dutasteride: A New 5‐alpha Reductase Inhibitor for Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Brown

Nuttall

2003

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARYDutasteride is a new 5‐alpha reductase inhibitor for the treatment of men with moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. It has been available in the UK since March 2003. It is a competitive inhibitor of both type I and type II isoforms of the 5‐alpha reductase enzyme that converts testosterone to the more potent androgen, dihydrotestosterone. Randomised controlled studies have shown dutasteride to be statistically more effective than placebo in reducing lower urinary tract symptoms and increasing maximum urinary flow rates. This is a consequence of a reduction in serum dihydrotestosterone and hormone dependent prostate volume. Dutasteride has also been shown to decrease the absolute risk of urinary retention and the need for prostate‐related surgery when compared to placebo taken over a 24‐month period. In this review article we discuss the pharmacology and clinical effects of dutasteride, a new dual‐acting 5‐alpha reductase inhibitor.

show abstract

Doxazosin in the treatment of benign prostatic hyperplasia. A review of the safety profile in older patients

Cited by 7 publications

References 12 publications

α1-Adrenergic Receptor Antagonists: Novel Therapy for Pituitary Adenomas

α1-Adrenergic Receptor Antagonists: Novel Therapy for Pituitary Adenomas

Frequent Episodic Vertigo is an Unexpected Side Effect of Flutamide

Dutasteride: A New 5‐alpha Reductase Inhibitor for Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Contact Info

Product

Resources

About